

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Steven Jungles, et al.	Confirmation No.:	4565
Serial No.:	10/563,418	Art Unit:	1618
Filed:	July 24, 2007	Examiner:	Rogers, James William
For:	Stable Tablet Formulation	Attorney Docket No.:	011808-0045-999 (CAM 120024-999045)

TERMINAL DISCLAIMER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

BIOMARIN PHARMACEUTICAL INC. is the assignee of the entire right, title and interest in and to the above identified application by virtue of an assignment from inventors Steven Jungles, Mark A. Henderson, Victoria Sluzky, and Robert Baffi to BIOMARIN PHARMACEUTICAL INC., which was recorded on January 21, 2009 at reel 022134 frame 0372.

BIOMARIN PHARMACEUTICAL INC. is the assignee of the entire right, title and interest in and to U.S. Patent No. 7,566,462 by virtue of an assignment from inventors Steven Jungles, Mark A. Henderson, Victoria Sluzky, and Robert Baffi to BIOMARIN PHARMACEUTICAL INC., which was recorded on April 17, 2009 at reel 022560 frame 0725.

Thus, title to the above-identified application, as well as U.S. Patent No. 7,566,462, is properly vested in BIOMARIN PHARMACEUTICAL INC.

BIOMARIN PHARMACEUTICAL INC. hereby disclaims the terminal part of any patent granted on the above identified application which would extend beyond the expiration date of U.S. Patent No. 7,566,462, and hereby agrees that any patent so granted on the above identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to U.S. Patent No. 7,566,462.

BIOMARIN PHARMACEUTICAL INC. further agrees that this agreement is to run with any patent granted on the above identified application and is to be binding upon the

grantee, its successors, and assigns.

BIOMARIN PHARMACEUTICAL INC. does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of U.S. Patent No. 7,566,462 in the event that said patent later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

The undersigned hereby confirms that she has reviewed the assignment and, to the best of her knowledge and belief, title is in the assignee seeking to take action in this matter and that she is empowered to act on behalf of BIOMARIN PHARMACEUTICAL INC.

The undersigned hereby declares that all statements made herein of her own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signed this 11 day of January 2011.

BIOMARIN PHARMACEUTICAL INC.

By: _____



Name: Luisa Bigornia
Title: Vice President of Intellectual Property
BIOMARIN PHARMACEUTICAL INC.
105 Digital Drive
Novato, CA 94949